Planning Capital Management Corp Stoke Therapeutics, Inc. Transaction History
Planning Capital Management Corp
- $151 Billion
- Q3 2024
A detailed history of Planning Capital Management Corp transactions in Stoke Therapeutics, Inc. stock. As of the latest transaction made, Planning Capital Management Corp holds 70 shares of STOK stock, worth $800. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 70
-0.0%
Holding current value
$800
Previous $946,000
8.99%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding STOK
# of Institutions
123Shares Held
57.6MCall Options Held
9.3KPut Options Held
35.2K-
Skorpios Trust8.91MShares$102 Million99.85% of portfolio
-
Black Rock Inc. New York, NY5.41MShares$61.8 Million0.0% of portfolio
-
Lynx1 Capital Management LP San Juan, PR5.19MShares$59.3 Million22.82% of portfolio
-
Redmile Group, LLC San Francisco, CA4.71MShares$53.9 Million3.79% of portfolio
-
Rtw Investments, LP New York, NY4.65MShares$53.2 Million0.91% of portfolio
About Stoke Therapeutics, Inc.
- Ticker STOK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,419,300
- Market Cap $451M
- Description
- Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. I...